NCT05832086 is a Phase 2 clinical trial of Fasting Mimicking Diet (FMD) in Prostate Adenocarcinoma, sponsored by Stephen Freedland.

Who is sponsoring NCT05832086?

NCT05832086 is sponsored by Stephen Freedland.

What drugs are being tested in NCT05832086?

Interventions in NCT05832086: Fasting Mimicking Diet (FMD), Standard Anti-Cancer Diet.

What condition does NCT05832086 study?

NCT05832086 studies Prostate Adenocarcinoma.

Is NCT05832086 still recruiting?

NCT05832086 is currently recruiting now. Last updated 7 April 2026.

Last reviewed 2026-04-07 · How we verify

NCT05832086

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes

Recruiting now Phase 2 Last updated 7 April 2026

What this trial tests

Phase 2 trial testing Fasting Mimicking Diet (FMD) in Prostate Adenocarcinoma in 138 participants. Currently enrolling.

Timeline

13 September 2023

Primary endpoint
30 September 2028

30 March 2029

Quick facts

Lead sponsor	Stephen Freedland
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	138
Start date	13 September 2023
Primary completion	30 September 2028
Estimated completion	30 March 2029
Sites	3 locations across United States

Drugs / interventions tested

Fasting Mimicking Diet (FMD)
Standard Anti-Cancer Diet

Conditions studied

Prostate Adenocarcinoma — all drugs for Prostate Adenocarcinoma →

Sponsor

Stephen Freedland

Who can join

Eligibility, male only, with Prostate Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 2, randomized two-armed, multi-site study of 138 patients with metastatic castrate sensitive prostate adenocarcinoma. Patients will be randomized 1:1 to receive the fasting mimicking diet, or usual diet. All patients will receive standard of care treatment for their prostate cancer. The fasting mimicking diet will be consumed for 5 days per month for a total of 6 months and will be monitored by trained research dietitians. This study aims to examine the effects of a fasting mimicking diet (5 days per month eating L-Nutra products only for 6 months) vs. usual diet on response to cancer treatment of metastatic castrate sensitive prostate adenocarcinoma.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Intermittent fasting and its impact on toxicities, symptoms and quality of life in patients on active cancer treatment.
Li Sucholeiki R, Propst CL, Hong DS, George GC. · · 2024 · cited 4× · PMID 38574507 · DOI 10.1016/j.ctrv.2024.102725
The advent of precision nutrigeroscience in cancer: from clinic towards molecular biology.
Gao Z, Liu Y, Cui Y, Han Y, et al · · 2026 · cited 2× · PMID 40850675 · DOI 10.1016/j.jare.2025.08.034

Verify or expand the search:

Other trials of Fasting Mimicking Diet (FMD)

Trials testing the same drug.

NCT04529161 — Olfactory and Taste Changes During Fasting Mimicking Diet (FMD) · NA · completed

Other recruiting trials for Prostate Adenocarcinoma

Currently open trials in the same condition.

NCT06831032 — Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response · NA · recruiting
NCT07285057 — Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance · Phase 2 · recruiting
NCT06957691 — Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Pro · Phase 2 · recruiting
NCT07025369 — Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With H · Phase 2 · recruiting
NCT06967961 — Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05832086 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Stephen Freedland
Last refreshed: 7 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05832086.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing